Meeting details menu

Meeting Authors
Meeting Abstracts
Keynote lectures
Oral communications
Poster presentations
Special symposia
Other

Acta Physiologica Congress

Back

Acta Physiologica 2008; Volume 192, Supplement 662
Belgian Society for Fundamental and Clinical Physiology and Pharmacology, Autumn Meeting 2007
11/17/2007-11/17/2007
Katholieke Universiteit Leuven, Leuven, Belgium


THE ROLE OF GLUTAMATE TRANSPORTERS IN ALZHEIMER (APP23) TRANSGENIC MICE
Abstract number: P-01

Schallier1 A., Massie1 A., Van Dam2 D., De Deyn2 P.P., Michotte1 Y., Smolders1 I.

1Research Group Experimental Pharmacology, Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium
2Laboratory of Neurochemistry & Behaviour, Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium

Introduction: Alzheimer's disease (AD) is a neurodegenerative central nervous system (CNS) disorder. AD is characterized pathophysiologically by regional neuronal loss. This loss may result from an excitotoxic process in which glutamate transporters may play an important role. Amyloid precursor protein (APP23) transgenic mice, a unique AD model, are known to cause early-onset familial AD. Until now, not much is known with respect to the glutamate transporters in AD. These transporters regulate excitatory neurotransmission and prevent glutamate-mediated excitotoxicity in the CNS. Three vesicular glutamate transporters (vGlut1-3) load glutamate up into synaptic vesicles. Glutamate transporter-1 (Glt-1) and glutamate aspartate transporter (Glast), the 2 glial high-affinity Na+/K+-dependent glutamate transporters, are responsible for removing extracellular glutamate in the CNS. Aim: In the present study, the possible changes in hippocampal expression level of the vGlut1-3, Glt-1 and Glast are examined by means of semi-quantitative Western blotting in 8 month old wild type (WT) and APP23 mice. Results: There is no change in expression in vGlut1 and vGlut2. On the contrary, there is a tendency to a downregulated expression in vGlut3 in APP23. Glast is significantly downregulated in APP23 mice compared to the WT mice and this is also the tendency for Glt-1. Discussion: The possible elevation of glutamate in the synaptic cleft is probably not due to an enhanced expression of the vGlut1, but can be a consequence of a decreased expression of Glt-1 and Glast.

To cite this abstract, please use the following information:
Acta Physiologica 2008; Volume 192, Supplement 662 :P-01

Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.

By continuing to browse this site you agree to us using cookies as described in our standard cookie policy .

CLOSE